04.27.17
Roche
1Q Revenues: 12.9 million CHF (+4%)
Comments:Pharmaceuticals Division sales were 10.2 million CHF, up 3%, driven mainly by Tecentriq and Perjeta, partially offset by lower sales of Tamiflu due to generic competition. In the U.S., sales were up 6%, led by recently launched medicines Tecentriq and Alecensa, as well as Xolair and MabThera/Rituxan. In Europe sales were up +1%, with Perjeta, Actemra/RoActemra and Herceptin as the main contributors to growth. Diagnostics Division sales grew 6%, primarily due to immunodiagnostic solutions.
1Q Revenues: 12.9 million CHF (+4%)
Comments:Pharmaceuticals Division sales were 10.2 million CHF, up 3%, driven mainly by Tecentriq and Perjeta, partially offset by lower sales of Tamiflu due to generic competition. In the U.S., sales were up 6%, led by recently launched medicines Tecentriq and Alecensa, as well as Xolair and MabThera/Rituxan. In Europe sales were up +1%, with Perjeta, Actemra/RoActemra and Herceptin as the main contributors to growth. Diagnostics Division sales grew 6%, primarily due to immunodiagnostic solutions.
